방사선종양학

본문글자크기
  • [Radiat Oncol.] Delta-radiomics signature predicts treatment outcomes after preoperative chemoradiotherapy and surgery in rectal cancer.직장암에서 델타-Radiomics 이용 수술전 항암화학방사선치료 결과 예측

    서울의대 / 전승혁, 송창훈, 김재성*

  • 출처
    Radiat Oncol.
  • 등재일
    2019 Mar 12
  • 저널이슈번호
    14(1):43. doi: 10.1186/s13014-019-1246-8.
  • 내용

    바로가기  >

    Abstract
    BACKGROUND:
    To develop and compare delta-radiomics signatures from 2- (2D) and 3-dimensional (3D) features that predict treatment outcomes following preoperative chemoradiotherapy (CCRT) and surgery for locally advanced rectal cancer.

    METHODS:
    In total, 101 patients (training cohort, n = 67; validation cohort, n = 34) with locally advanced rectal adenocarcinoma between 2008 and 2015 were included. We extracted 55 features from T2-weighted magnetic resonance imaging (MRI) scans. Delta-radiomics feature was defined as the difference in radiomics feature before and after CCRT. Signatures were developed to predict local recurrence (LR), distant metastasis (DM), and disease-free survival (DFS) from 2D and 3D features. The least absolute shrinkage and selection operator regression was used to select features and build signatures. The delta-radiomics signatures and clinical factors were integrated into Cox regression analysis to determine if the signatures were independent prognostic factors.

    RESULTS:
    The radiomics signatures for LR, DM, and DFS were developed and validated using both 2D and 3D features. Outcomes were significantly different in the low- and high-risk patients dichotomized by optimal cutoff in both the training and validation cohorts. In multivariate analysis, the signatures were independent prognostic factors even when considering the clinical parameters. There were no significant differences in C-index from 2D vs. 3D signatures.

    CONCLUSIONS:
    This is the first study to develop delta-radiomics signatures for rectal cancer. The signatures successfully predicted the outcomes and were independent prognostic factors. External validation is warranted to ensure their performance.

     


    Author information

    Jeon SH1, Song C2, Chie EK1, Kim B3, Kim YH4, Chang W4, Lee YJ4, Chung JH1, Chung JB2, Lee KW5, Kang SB6, Kim JS7.
    1
    Department of Radiation Oncology, Seoul National University College of Medicine, 101 Daehak-ro, Jongno-gu, Seoul, 03080, Republic of Korea.
    2
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea.
    3
    Division of Biomedical Engineering, Hankuk University of Foreign Studies, 81 Oedae-ro, Mohyeon-eup, Cheoin-gu, Yongin, 17035, Republic of Korea.
    4
    Department of Radiology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea.
    5
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea.
    6
    Department of Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea.
    7
    Department of Radiation Oncology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82 Gumi-ro 173beon-gil, Bundang-gu, Seongnam, 13620, Republic of Korea. jskim@snubh.org.

  • 키워드
    Chemoradiotherapy; Delta-radiomics; Radiomics; Rectal cancer
  • 덧글달기
    덧글달기
       IP : 3.141.24.134

    등록